Anzeige
Mehr »
Dienstag, 24.02.2026 - Börsentäglich über 12.000 News
Von Polen bis Virginia Beach- zündet hier der nächste Smallcap-Turbo?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 920657 | ISIN: FR0000120578 | Ticker-Symbol: SNW
Tradegate
24.02.26 | 17:54
81,08 Euro
+0,82 % +0,66
1-Jahres-Chart
SANOFI SA Chart 1 Jahr
5-Tage-Chart
SANOFI SA 5-Tage-Chart
RealtimeGeldBriefZeit
81,1081,2718:18
81,0981,3118:18

Aktuelle News zur SANOFI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:36Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis4
15:34Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis610Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study...
► Artikel lesen
MoSanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA22
SANOFI Aktie jetzt für 0€ handeln
MoL'Oréal Influences Sanofi CEO Ouster and Successor Appointment48
FrManuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit20
FrSanofi sued by Texas AG for running kickback scheme for doctors8
FrTexas sues Sanofi, claiming kickbacks to doctors6
FrTexas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions26
DoMerck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AstraZeneca's Beyfortus10
DoSanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study16
17.02.Sanofi - S-8, Securities to be offered to employees in employee benefit plans12
17.02.Sanofi: Filing of the 2025 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report479Filing of the 2025 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form...
► Artikel lesen
17.02.Sanofi - 20-F, Annual and transition report of foreign private issuers4
17.02.JPMORGAN stuft SANOFI auf 'Neutral'840NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi auf "Neutral" mit einem Kursziel von 95 Euro belassen. Analyst Richard Vosser wertete in einem am Dienstag vorliegenden...
► Artikel lesen
17.02.Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post32
17.02.Sanofi, Teva Report Positive Phase 2b Results For Duvakitug420PARIS (dpa-AFX) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative...
► Artikel lesen
17.02.Sanofi - 6-K, Report of foreign issuer4
17.02.Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data30
17.02.Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn's disease28
17.02.Sanofi: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease1.677Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug...
► Artikel lesen
Weiter >>
863 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,68